R ecognition of ligands on target cells by cognate receptors on acceptor cells such as B cells, T cells, or NK cells can
lead to transfer of the ligand and closely associated membrane fragments from the target cell to the acceptor cell (1) (2) (3) (4) . In this endocytic reaction, called trogocytosis or nibbling, both the captured ligand and its receptor on the acceptor cell are internalized. We have recently demonstrated that a similar transfer occurs in vitro when B cells opsonized with anti-CD20 mAb rituximab (RTX) 3 are reacted with either PBMC or monocytic THP-1 cells (5) . In this case the RTX-CD20 immune complexes (IC) on the target cell serve as ligands for Fc␥RI on the acceptor cell.
We established this in vitro system as a model to investigate the mechanism of loss of bound RTX and CD20 from targeted circulating malignant B cells, which occurs in vivo when patients with chronic lymphocytic leukemia (CLL) are treated with doses of RTX ranging from as low as 60 mg/m 2 up to the usual 375 mg/m 2 doses (6, 7). Soon after completion of RTX infusion, substantial numbers of viable malignant B cells are demonstrable in the bloodstream. These cells have markedly reduced levels of CD20 and have very little bound RTX. Moreover, these B cells are tagged covalently with C3dg, indicating that during the infusion the cells must have been previously opsonized with RTX, which promotes complement activation and deposition of C3b activation fragments. We have also demonstrated in several in vitro models that this loss of CD20 and bound RTX can occur in the complete absence of complement, thus precluding a causative role for C3b/ C3dg in the CD20 loss (5, 8) . This removal of cell-bound RTX and CD20 by acceptor cells, which we termed "shaving", is quite similar to trogocytosis and may be responsible for the phenomenon of antigenic modulation seen in earlier cancer immunotherapy studies (9 -14) . For example, treatment of T cell lymphoma patients with the anti-CD5 mAb T101 led to rapid and profound reduction in the level of CD5 on malignant T cells in the bloodstream (14) . The mechanism responsible for this antigenic modulation was not known, but our studies of shaving and those of other investigators on trogocytosis provide a likely mechanism for the observed loss of CD5, namely removal of the T101/CD5 IC by Fc␥R-expressing acceptor cells. All of these reactions, that is, trogocytosis, shaving, and antigenic modulation, may share a common pathway for processing of targeted ligands removed from donor cells and taken up by acceptor cells.
To further characterize shaving of RTX-CD20 complexes and the relationship of this reaction to trogocytosis, we used the membrane dye PKH26 to test for the transfer of membrane fragments from RTX-opsonized donor cells to acceptor THP-1 cells. Multispectral image analysis and flow cytometry experiments revealed that both RTX and PKH26 are taken up by the acceptor cells, and this finding extends our previous work in this system (5) . We investigated the possible generality of these reactions with respect to the use of other immunotherapeutic mAbs in targeting malignant cells. Flow cytometry and fluorescence microscopy were employed to examine three different mAb-opsonized/donor cell pairs: mAb T-101/MOLT-4 cells; trastuzumab (TRA, used in the treatment of breast cancer (15, 16) )/BT-474 cells; and cetuximab (CET, used in the treatment of colorectal and other cancers (17, 18) )/ SCC-25 cells. In all three cases we observe similar reactions that closely follow the tenets defined for trogocytosis: transfer of donor cell-bound mAb/target Ag IC and membrane fragments to the acceptor cells, as well as internalization of acceptor cell Fc␥RI.
Materials and Methods

Cells
The Her2/Neu ϩ BT-474 cell line and the CD5 ϩ MOLT-4 cell line were obtained from American Type Culture Collection. The epidermal growth factor receptor-positive SCC-25 cell line was kindly provided by Dr. Christopher Thomas (University of Virginia). BT-474 cells and MOLT-4 cells were cultured in RPMI 1640 containing 10% FBS, 100 U/ml penicillin, and 100 g/ml streptomycin (all from Invitrogen). SCC-25 cells were cultured in DMEM/F-12 medium containing 10% FBS, 100 U/ml penicillin, 100 g/ml streptomycin, 20 mM HEPES, and 500 ng/ml hydrocortisone. BT-474 and SCC-25 cells were trypsinized before their use in experiments. These three cell types, along with Daudi, Raji, and Z138 cells (5, 8, 19) , were used as donor cells. THP-1 cells were used as acceptor cells in most experiments and were activated by incubation with PMA or with all-trans retinoic acid (RA) (5) . In some experiments primary monocytes isolated from PBMC were used as acceptor cells without any previous activation (20, 21) .
Reagents and Abs
PKH26 was obtained from Sigma-Aldrich; human IgG and mouse (Ms) IgG from Lampire Biological Laboratories; RTX, TRA, and CET from the University of Virginai hospital pharmacy; mAb M22 (mouse IgG1) and mAb 10.1 (mouse IgG1), both specific for Fc␥RI, from Medarex and Caltag Laboratories, respectively; PE goat (Gt) anti-Ms IgG (Fc-specific) from Jackson ImmunoResearch Laboratories; biotinylated (bt) anti-CD11b from BD Pharmingen and bt anti-CD14 and tricolor (PE-Cy5) streptavidin (SA) from Caltag Laboratories. mAb T101 (mouse IgG2a) was kindly provided by Dr. Jorge Carrasquillo (National Institutes of Health). mAb HB43 (mouse IgG1), specific for human IgG Fc (22) , and mAb IV.3 (mouse IgG2b, derived from the HB217 cell line), specific for Fc␥RII (CD32), were purified from hybridomas obtained from American Type Culture Collection. mAbs were labeled with Alexa (Al) 488 (Invitrogen), according to the manufacturer's instructions. Al647 Gt anti-Ms IgG1 (Fc-specific) and Al594-and Al647-labeled SA were from Invitrogen. F(abЈ) 2 of TRA and CET were obtained by pepsin digestion of intact mAbs as follows. The mAbs were dialyzed into 0.1 M acetate (pH 7) and then titrated with 1.5 M citric acid, to a final pH of 3.5. Pepsin was dissolved at 2 mg/ml in 1.5 M citric acid (pH 3.5), and the mAb and pepsin solutions were prewarmed to 37°C. They were then combined at a mAb/pepsin ratio of 80:1 (w/w) and incubated at 37°C for 60 min. The digestion was stopped with addition of 1 N NaOH to raise the pH to 7 and the sample was dialyzed into borate saline (pH 7.8). FITC-labeled fragments were prepared and tested for complete removal of Fc regions by binding them to cognate cells followed by probing with Al647 mAb HB43, which is specific for the Fc region of human IgG (22) . mAb HB43 bound well to cells opsonized with intact TRA and CET, but virtually no mAb HB43 was bound to cells opsonized with F(abЈ) 2 TRA or CET (not shown).
Protocols for trogocytosis experiments
Raji or Z138 cells, MOLT-4 cells, trypsinized BT-474 or trypsinized SCC-25 cells (ϳ10 7 cells/ml) were labeled with 4 M PKH26 for 2 min followed by quenching with RPMI 1640 containing 10% FBS and after two washes were incubated with and without 10 g/ml Al488-labeled mAbs (RTX, T101, TRA, or CET, respectively) in RPMI 1640 media for 20 min at 37°C with gentle shaking. The opsonized cells were washed with cold BSA/PBS to remove unbound mAb and then resuspended in media. The nonopsonized (naive) or Al488 mAb-opsonized PKH26-labeled donor cells were combined with PMA-treated adherent acceptor THP-1 cells in 24-well plates, or with RA-treated THP-1 cells in tubes. Various ratios of donor cells/acceptor cells were used, but typically 2-10 ϫ 10 5 donor cells were added to 1 ϫ 10 6 THP-1 cells, giving a ratio of donor cells/acceptor THP-1 cells between 1:5 and 1:1. The plates were centrifuged at 300 ϫ g for 15 s, and then incubated for various times (usually 45 min) at 37°C in 5% CO 2 . Zero-time control samples, consisting only of opsonized or naive donor cells in RPMI 1640 medium, were subjected to identical conditions. After these incubations the samples were placed on ice for 10 min, and then the zero-time control donor cells were added to the THP-1 cells and all samples were immediately quenched by addition of cold BSA/PBS. All experiments were performed in duplicate. In some experiments, THP-1 cells were preincubated for 60 min at 37°C with 2 mg/ml human IgG or with 30 g/ml anti-Fc␥R mAbs, and then used in the trogocytosis reactions following the above procedures. Blocking mAbs specific for Fc␥RI (mAb 10.1) and Fc␥RII (mAb IV.3) were used at concentrations (30 g/ml) that were previously demonstrated to lead to saturation of binding to these receptors (23) (24) (25) (26) . After the trogocytosis reaction, the donor and acceptor cells were analyzed in a variety of assays, as detailed below.
Analysis of target cells for loss of opsonizing mAb and loss of targeted Ag (shaving)
In experiments employing PMA-treated adherent THP-1 cells, after the trogocytosis reaction donor cells were separated from THP-1 cells by gentle aspiration, and then residual THP-1 cells were removed from the wells by vigorous pipetting. In experiments using RA-treated THP-1 cells, donor cells were not separated from the THP-1 cells. The amount of residual opsonizing mAb on the donor cells was determined by flow cytometry by gating on FL2 ϩ PKH26-labeled donor cells or by multispectral image analysis. In tests for loss of targeted epitope (i.e., shaving) the Al488 mAbopsonized or nonopsonized donor cells were reprobed with the same Al488 mAb used in the initial opsonization step ("reopsonized") in the presence of 2 mg/ml Ms IgG to block any nonspecific binding. The cells were then washed with PBS and examined by flow cytometry. In certain experiments shaved cells and control cells were stained with either FITC annexin V or with TOPRO-3 (Invitrogen) to determine whether shaving promoted apoptosis or direct killing of the cells (5, 8) .
Analysis of THP-1 cells for uptake of opsonizing mAb, PKH26, and for Fc␥RI levels
All probing steps were performed for 1 h on ice. Following their removal from the 24-well plates, THP-1 cells were probed in the presence of Ms IgG with a cocktail of bt anti-CD11b and bt anti-CD14, washed with BSA/ PBS, and then secondarily probed with PE-Cy5 (tricolor) for multispectral image analyses or with either Al594 SA or Al647 SA for fluorescence microscopy or with Al647 SA for flow cytometric analysis. To monitor Fc␥RI levels, THP-1 cells were probed, before the trogocytosis reaction, with Al488 mAb M22, specific for a site on Fc␥RI that is not blocked by bound human IgG ligand (27) . After the trogocytosis reaction the THP-1 cells were analyzed for residual bound Al488 mAb M22 and probed secondarily with PE Gt anti-Ms IgG (Fc-specific) or with Al647 Gt anti-Ms IgG1 (Fc-specific) to determine the percentage of Al488 mAb M22 remaining on the surface of the THP-1 cells.
Flow cytometry, multispectral image analysis, and fluorescence microscopy
Flow cytometry was performed using a dual-laser FACSCalibur cytometer (BD Biosciences). Mean fluorescence intensities were converted to molecules of equivalent soluble fluorochrome (MESF) using standard fluorescent beads (Spherotech). Multispectral image analysis was performed on an ImageStream imaging cytometer (Amnis) as previously described (28, 29) . Fluorescence microscopy was performed under oil at high magnification (ϫ100) using a BX40 fluorescent microscope (Olympus). Images were captured with a digital camera and visualized with MagnaFire analysis software.
Acid wash protocol
To distinguish mAb bound to the cell surface from internalized mAb, donor cells were opsonized with Al488 mAbs and then incubated for 5 min at pH 2.5 in RPMI 1640 medium supplemented with 2% FBS (30) . This procedure has been used to identify ligands bound to the external surface of a cell, which are released due to incubation at low pH. After incubation the cells were washed twice in PBS and then subjected to flow cytometry analyses. This same procedure was used to examine both donor and acceptor cells after the shaving reaction.
Results
Membrane fragments are transferred to acceptor cells
We have previously demonstrated that THP-1 cells remove RTX-CD20 complexes from B cells (5) . Since CD20 is an integral membrane protein, we investigated whether donor B cell membrane lipids are also transferred. Raji cells were stained with the membrane dye PKH26, and then the cells were opsonized with Al488 RTX and incubated with THP-1 cells at 37°C for 45 min. After the reaction, the mixtures were probed with a cocktail of bt antiCD11b and bt anti-CD14, followed by SA-PE-Cy5 to positively identify the THP-1 cells, and then the mixtures were examined by multispectral image analysis. This technique allows simultaneous spectral and image analysis of thousands of cells per sample (28) , thus allowing for detailed and representative inspections of large numbers of individual cells. The dot plots in Fig. 1, A and B, (time ϭ 0 min) show the initial distribution of the Al488 RTX and PKH26 signals for the two populations. After 45 min the THP-1 cells (yellow dots) had clearly taken up both Al488 RTX and PKH26 (Fig. 1, C and D ; compare C to A and D to B). There was a decrease in the Al488 RTX signal on the Raji cells (red dots) but the signal due to the PKH26 dye did not appear to change on the Raji cells, likely because only a small percentage of membrane lipid is removed from donor cells during the trogocytosis reaction (31) . Inspection of images of individual cells (Fig. 1E-H) clearly reveal that the THP-1 cells had taken up both Al488 RTX and PKH26 after 45 min (compare Fig. 1G with Fig. 1H ). Some Raji cell/THP-1 cell pairs were discernable and appeared to be connected in an immunologic synapse; after 45 min, both the Al488 and PKH26 signals were visible on both cells (Fig. 1I) .
To place these observations in a quantitative context, we measured the kinetics of transfer of Al488 RTX and PKH26 from Raji cells to THP-1 cells by either multispectral image analysis or with conventional flow cytometry (Fig. 2) . The decrease in the Al488 signal on the Raji cells occurred coincidentally with the increase of the Al488 signal on the THP-1 cells (Fig. 2, A and B) , and both techniques gave similar results. Moreover, the rate of uptake of the membrane dye PKH26 by the THP-1 cells (Fig. 2 , C and D, filled circles) roughly paralleled the rate of increase of the Al488 signal on these cells (Fig. 2, A 
Extension of trogocytosis to three other mAb/donor cell systems
We extended this in vitro assay system to examine trogocytosis of donor cells opsonized with mAbs T101, CET, or TRA, and then reacted with THP-1 cells at a 1:10 donor cell/acceptor cell ratio. In common with our observations for RTX-opsonized cells, the results of the experiment illustrated in Fig. 3A indicate that large amounts of the bound Al488 mAbs were removed from the donor cells after reaction with THP-1 cells (filled bars), and the loss of bound mAb could be significantly inhibited by human IgG (striped bars). In the next series of experiments the ratio of donor cells/ acceptor cells was set at 1:1 to measure both loss of Al488 mAb from donor cells and mAb uptake by the acceptor cells. Significant amounts of the Al488-labeled mAbs were removed from the target cells and taken up by the acceptor THP-1 cells (Figs. 3 , B and C, filled bars); both loss and uptake were substantially inhibited by human IgG (striped bars), providing evidence that these processes are mediated by Fc␥R. Moreover, as defined by PKH26 fluorescence, membrane fragments from these donor cells were also taken up by the acceptor THP-1 cells (Fig. 3D ), and this reaction was also blocked by human IgG. As observed with the RTX/Raji cell pair, much less PKH26 was taken up by the acceptor cells if the target cells were not opsonized with mAbs ( Fig. 3D , gray hatched bars); this low level of PKH26 uptake was similar to the amount of PKH26 taken up by the cells when the reaction with opsonized cells was blocked by human IgG.
To verify that the uptake of the PKH26 illustrated in Fig. 3D was not simply a spectral overlap artifact caused by uptake of the Al488-labeled opsonizing mAbs, the experiment illustrated in Fig.  3E was performed with PKH26-labeled cells that were opsonized with unlabeled mAbs, and quite similar results were achieved. That is, uptake of PKH26 by THP-1 cells from donor cells opsonized with unlabeled mAbs is comparable to that obtained when these cells were opsonized with the Al488-labeled mAbs. Once again, substantially less of the membrane dye was taken up from naive cells relative to mAb-opsonized cells (Fig. 3E , gray hatched bars vs black bars).
To generalize our findings we also tested freshly isolated human monocytes for their potential to serve as acceptor cells and promote trogocytosis. The results in Fig. 4 in which monocytes were tested as acceptor cells are quite similar to those illustrated in Fig.  3B -D in which THP-1 cells were examined. Indeed, all three Al488 mAbs were removed from their respective target cells and taken up by the monocytes, and substantial transfer of the PKH26 dye from donor cells to monocytes was only seen when the donor cells were opsonized with their respective mAbs (Fig. 4) . These transfer reactions were inhibited when the monocytes were preincubated with human IgG, again providing evidence that Fc␥R play an important role in the trogocytosis reaction for these primary cells as well.
To further investigate the role of Fc␥R in trogocytosis, we examined the potential of blocking mAbs, specific for Fc␥RI and Fc␥RII, to inhibit the reaction. The Fc␥R-specific mAbs were able to modestly block both removal of the Al488 mAbs from the donor cells and uptake of Al488 mAbs and PKH26 by the THP-1 cells in all four systems (Fig. 5 ), but blocking was not nearly as effective as was observed with human IgG (Figs. 3 and 4) . Human IgG can contain aggregates that can bind with high affinity to Fc␥R (32) , and considerably higher concentrations of human IgG were used, likely explaining the higher level of inhibition observed. Fig. 5A also shows that the percentage of Al488 RTX removed from the Raji cells (80%) was greater than the percentage of the other mAbs removed from their respective donor cells (25-50%), possibly suggesting that the nature of the Ag chelated by a given mAb may influence the degree of trogocytosis (see Discussion).
Previously we reported that F(abЈ) 2 of cell-bound RTX do not promote shaving (5), and we have now extended this observation to the F(abЈ) 2 of TRA and CET. FITC-labeled F(abЈ) 2 of the mAbs bound to their target epitopes on donor cells, and prior opsonization with the intact cognate IgG mAbs blocked this binding (Fig.  6, A and B) . When cells were opsonized with F(abЈ) 2 or with intact IgG mAbs and then reacted with THP-1 cells for 45 min at 37°C, there was little if any loss of bound F(abЈ) 2 , but substantial fractions of the intact IgG mAbs were once again removed (Fig. 6, C  and D) . When the cells were subjected to conditions of reopsonization, which allows for a determination of the availability of the targeted epitopes, again only the cells opsonized with intact mAbs were demonstrated to have undergone shaving (Fig. 6, E and F) . These results provide additional evidence that recognition of cellbound IgG by Fc␥R on the acceptor cell is a key step in the shaving reaction.
We next used fluorescence microscopy to visualize transfer of Al488-labeled T101, TRA, or CET from opsonized donor cells to THP-1 acceptor cells. Al488 mAb-opsonized donor cells and THP-1 cells were incubated at a 1:1 ratio for 45 min at 37°C, and then stained with bt anti-CD11b and bt anti-CD14 followed by Al594 SA to identify the THP-1 cells. For each of the three mAbs, the fluorescent micrographs clearly demonstrate uptake of the green Al488 mAb by red THP-1 cells (Fig. 7) .
Transfer of opsonizing mAbs is not due to phagocytosis or simple dissociation
It is possible that the internalization of the Al488 mAbs and/or PKH26 by the acceptor THP-1 cells might be due in part to phagocytosis of the donor cells by the acceptor THP-1 cells. We were able to rule out this reaction in our previous studies of the RTX-Z138 cell/THP-1 cell system based on the high level of recovery of donor cells under conditions that promoted shaving (5) . In the present studies we quantitated recovery of donor cells by counting constant volume aliquots of the reaction mixtures soon after quenching the shaving reaction. In a representative experiment, recovery of TRA-opsonized BT-474 cells after the shaving reaction averaged 17,000 Ϯ 1,100 cells, and recovery of these cells under control conditions that precluded shaving (THP-1 cells were preblocked with human IgG) averaged 16,000 Ϯ 2,000 cells. Comparable results for recovery of donor cells in the CET/SCC-25 system were 9,100 Ϯ 700 and 7,500 Ϯ 100 cells, respectively. These results indicate that little if any phagocytosis occurred during the shaving reaction. Finally, inspection of fields by fluorescence microscopy such as those illustrated in Fig. 7 did not reveal any obviously phagocytosed cells.
We performed control experiments to determine whether the uptake of the opsonizing mAbs and PKH26 by the THP-1 cells could have resulted from passive dissociation of the mAb and PKH26 dye from the donor cells into the medium, rather than by the active trogocytosis mechanism we have proposed. First we examined the degree of dissociation of the Al488 mAbs from donor cells after 45 min at 37°C in the absence of THP-1 acceptor cells, compared with holding the cells on ice. In agreement with the findings of Teeling et al. (33) , the RTX sample was modestly labile; the percentage of Al488 signal lost was ϳ15% for RTXopsonized cells that were incubated at 37°C. However, there was Ͻ3% dissociation for the other mAb-opsonized donor cells, and loss of PKH26 from all four donor cell types was Ͻ3%. We next tested the ability of THP-1 cells to take up either Al488 mAb or PKH26 potentially released into the medium by dissociation from donor cells. PKH26-stained, Al488 mAb-opsonized donor cells were first incubated in the absence of THP-1 cells for 45 min at 37°C. The donor cells were then removed by centrifugation and the cell-free supernatant was added to THP-1 cells. After a 45-min incubation at 37°C, the THP-1 cells were quenched and analyzed by flow cytometry. Uptake of the opsonizing Al488 mAb and PKH26 by the THP-1 cells was negligible (Ͻ2% of the positive controls, data not shown), thus ruling out passive dissociation and uptake as a transfer mechanism.
Tests for internalization of opsonizing mAbs by donor cells
It is possible that a fraction of the Al488-labeled mAbs was internalized by the substrate donor cells, either during the initial opsonization reaction or as a consequence of interaction with the THP-1 cells. To address this question, we subjected the donor cells, both after initial opsonization and after the shaving reaction, to acid wash procedures (30) to distinguish surface-bound mAbs from mAbs that had been internalized. We also examined THP-1 cells with the acid wash procedure after the shaving reaction, at which time they had taken up Al488-labeled mAbs from the donor cells. The results (first two bars on the left in Fig. 8 ) indicate that after opsonization, between 75% and 90% of bound mAbs could be released by acid wash for the four mAb/donor cell pairs under investigation, thus indicating that most of the mAbs were bound to the cell surfaces and not internalized during opsonization. Moreover, the acid wash did not appear to induce irreversible denaturation of the epitopes targeted by the mAbs, because after the acid wash and a reequilibration to neutral pH, the cells were again capable of binding the cognate mAbs (third bar from the left in each graph of Fig. 8 ). As already demonstrated, a substantial fraction of the mAbs could be shaved off the donor cells by THP-1 acceptor cells (fourth set of bars from the left of Fig. 8 ) and most of the material that was not removed by the THP-1 cells could still be removed by a subsequent acid wash, indicating that reaction with THP-1 cells did not lead to any appreciable internalization of the Al488 mAbs by the donor cells; that is, most of the bound mAbs that were not removed from the donor cells in a single pass of shaving were indeed still located on the cell surface. Finally, a considerably different pattern was evident when the THP-1 cells were subjected to acid wash after the shaving reaction (right sides of each graph in Fig. 8) . The results indicate that most of the Al488 mAbs taken up by the THP-1 cells could not be released by the acid wash, which is consistent with internalization of the mAbs by the THP-1 cells as a consequence of the trogocytosis/shaving reaction.
Effects of shaving on cell viability
We previously reported that THP-1 cell-promoted shaving of CD20 from RTX-opsonized Z138 cells neither killed the Z138 cells nor rendered them apoptotic (5), and we have now generalized this observation to two of the mAb-donor cell pairs in the present system. As presented in Table I , we find that reaction of mAb-opsonized donor cells with THP-1 cells for 45 min at 37°C followed by quenching with human IgG and cold BSA/PBS does not kill the cells or render them apoptotic. Only a small percentage of these donor cells were positive for the annexin V or TOPRO-3 stains, nearly identical to the values obtained for the 0-min control samples consisting of opsonized donor cells mixed with THP-1 
Dose-response studies and the effects of variations in cell ratios
We next investigated whether the degree of mAb opsonization for one representative mAb/donor cell pair, Al488 TRA/BT-474 cells, would influence the degree of trogocytosis. The results in Fig. 9A indicate that over a wide range of TRA concentrations used for opsonization, ϳ50% of the Al488 TRA initially bound to BT-474 cells was removed during incubation with THP-1 cells. Consistent with this finding, considerably more Al488 TRA was taken up by the THP-1 cells which were reacted with the most heavily opsonized BT-474 cells (Fig. 9B) . Both the loss of Al488 by the donor cells and the gain of Al488 by the acceptor cells were inhibited in the presence of 2 mg/ml human IgG. Next, for the T101/MOLT-4 system, we held the degree of opsonization constant at 10 g/ml Al488 mAb T101 and varied the donor cell/acceptor cell ratio (Fig.  9C) . Not surprisingly, we find that as the donor cell/acceptor cell ratio increased, the amount of Al488 mAb T101 taken up by the acceptor cells increased. This result suggests that a single acceptor cell is capable of taking up mAb ligands from more than one donor cell. Finally, similar results were respectively obtained in both dose-response studies and in experiments in which cell ratios were varied, based on using T101-opsonized MOLT-4 cells and CETopsonized SCC-25 cells, as well as on TRA-opsonized BT-474 cells and CET-opsonized SCC-25 cells (results not shown).
The role of Fc␥RI in the internalization reaction
A key late step in the endocytic process of shaving or trogocytosis is the internalization by the acceptor cell of the transferred ligand and the cognate receptor of the acceptor cell. Our previous work using RTX-opsonized Z138 cells as donor cells indicated that Fc␥RI is the receptor principally responsible for removal of RTX (5), and therefore we first tested for Fc␥RI internalization during incubation of THP-1 cells with RTX-opsonized Z138 cells. THP-1 cells were first labeled with Al488 mAb M22, which binds to Fc␥RI at a site not blocked by bound human IgG (27) , and then reacted with RTX-opsonized Z138 cells for 45 min at 37°C. To determine whether mAb M22 was still bound to Fc␥RI on the surface of the THP-1 cells or had been internalized, these reaction samples were probed secondarily with PE anti-Ms IgG (Fc-specific) after the trogocytosis reaction. Compared with the 0-time controls, there was a modest reduction (ϳ30%) in the amount of Al488 mAb M22 associated with THP-1 cells after reaction with donor cells (Fig. 10A) , likely due to passive dissociation of the mAb. However, as shown in Fig. 10B , compared with the 0-time controls, far less mAb M22 was detectable on the THP-1 cell surface after incubation with opsonized donor cells for 45 min at 37°C (ϳ70% reduction in signal). These results suggest that much of the residual cell-associated mAb M22 (and presumably the Fc␥RI to which it was bound) had indeed been internalized as a consequence of the trogocytosis reaction. We next applied this paradigm to all four mAb/donor cell pairs, except the RTX-opsonized donor B cells were Raji cells in this instance. The acceptor THP-1 cells were again first reacted with Al488 mAb M22 (IgG1 isotype) before the trogocytosis reaction (Fig. 10C) and probed after the trogocytosis reaction with Al647 Gt anti-Ms IgG1 (Fig. 10D) . Use of Al647 Gt anti-Ms IgG1 in this experiment was necessary because the PE anti-Ms IgG would have reacted with the Ms mAb T101 as well as with mAb M22, but the Al647 Gt anti-Ms IgG1 will not react with mAb T101 (isotype IgG2a) and thus recognizes only mAb M22. Similar to the results above, after the 45-min trogocytosis reaction there was modest reduction in signal (ϳ15%) of Al488 mAb M22 associated with the THP-1 cells (Fig. 10C) , compared with the 0-time controls. However, when the cells were probed for surface-bound mAb M22, the signals were reduced by at least 40% compared with the 0-time controls (Fig. 10D) , indicating that much of the cell-bound Al488 mAb M22 had been internalized, presumably along with Fc␥RI. Finally, there was no internalization of cell-bound mAb M22 when the THP-1 cells were incubated with any of the nonopsonized donor cells (results not shown).
We also studied the internalization phase of trogocytosis by probing cells with mAb HB43, which is specific for the Fc region of human IgG (22) , and which should bind to TRA and CET when these human IgG1 mAbs are bound to the surface of BT474 and SCC-25 cells, respectively. However, if these two mAbs are taken up by THP-1 cells and internalized, they will not be detected on the THP-1 cells by probing with mAb HB43. To test this hypothesis we used a three-color fluorescence microscopy paradigm: BT474 and SCC-25 cells were opsonized with Al488-labeled TRA and CET, respectively, and then reacted with THP-1 cells; after reaction the cell mixtures were probed with Al546 mAb HB43 to detect surface-bound TRA or CET, and with a cocktail of bt antiCD11b and bt anti-CD14, followed by Al647 SA, to identify THP-1 cells. Inspection of the bright field (Fig. 11A ) and fluorescent images reveals red Al647 THP-1 cells (Fig. 11B ) that had taken up green Al488-labeled TRA or CET (Fig. 11C) . However, these THP-1 cells were not stained with Al546 mAb HB43 (Fig.  11D) , indicating that the transferred Al488 mAbs had been internalized by the THP-1 cells. The mAb-opsonized donor cells with residual Al488 mAb appear yellow when stained with Al546 mAb HB43, and thus serve as positive staining controls (Fig. 11E) .
Direct tests for shaving of mAb-targeted epitopes
Our clinical reports of shaving of patient CLL cells after RTX infusion, as well as our in vitro observations of shaving of RTXopsonized B cells by acceptor cells, are based on a key finding: compared with 0-time controls, the shaved B cells have considerably reduced RTX binding capacity, which is revealed when the cells are reopsonized with RTX; this reduction in binding capacity indicates loss of CD20 (5-7). After the usual incubation of mAbopsonized donor cells with THP-1 cells, we used this reopsonization paradigm to test for loss of cell surface Ag for the three mAbdonor cell pairs under investigation. The results for mAb T101-opsonized MOLT-4 cells reacted with THP-1 cells provide unambiguous evidence for CD5 shaving (Fig. 12A) . In the nonopsonized control there was little, if any, loss of the target Ag (97% of the time 0 signal remained). However, MOLT-4 cells that were first opsonized with Al488 mAb T101 and then reacted with THP-1 cells had substantially reduced mAb T101 binding capacity when they were reopsonized with Al488 mAb T101 after the trogocytosis reaction (29% of the 0-time control). In agreement with our studies for the RTX-CD20 system, the mAb T101-mediated shaving reaction is blocked by human IgG (Fig. 12A) , again suggesting that the reaction is mediated by Fc␥R. Comparable analyses for Al488 TRA/BT-474 and Al488 CET/SCC-25 systems also demonstrated shaving, based on the reduced mAb binding capacity of cells that were first opsonized with their respective Al488 mAbs (76% and 36% of the 0-time controls, respectively, Fig. 12 , B and C). Once again, nonopsonized donor cells suffered little, if any, loss of mAb binding capacity, and shaving could be blocked by preincubation of the acceptor THP-1 cells with human IgG. These results demonstrate that, as we showed for RTX (5), acceptor cells cannot only remove the opsonizing mAb, they also remove its target Ag from the donor cells in these three mAb/donor cell combinations.
Discussion
We have reported previously that after RTX binds to CD20 on B lymphocytes, the constituents of the IC (both RTX and CD20) can be removed (shaved) from these cells and taken up and internalized by acceptor cells that express Fc␥R (5) . This report presents three key new findings. First, we can now further describe the shaving reaction as being quite similar, if not identical, to a previously reported phenomenon, trogocytosis (1-4) , as revealed by the concerted uptake of the membrane dye PKH26 when mAb/cell surface Ag IC are removed from the donor cells (Figs. 1-4) . Second, we have been able to extend and generalize our observations of Fc␥R-mediated trogocytosis/shaving beyond the RTX/B cell system to include several other therapeutic mAb/donor cell pairs and cell types: T101/MOLT-4 (T lymphoblasts, models for T cell lymphoma); TRA/BT-474 (epithelial cells, models for breast cancer); and CET/SCC-25 (keratinocytes, models for head and neck cancer). Third, cell types that have been reported to mediate trogocytosis have included B cells, T cells, NK cells, and dendritic cells (1, 3, 4, 34) , and thus monocytes would not necessarily be expected to mediate trogocytosis. We have now shown that both THP-1 cells and freshly isolated human monocytes indeed execute trogocytosis.
Fc␥R-promoted recognition and binding of both soluble and particulate IgG-containing IC by acceptor cell monocyte/macrophages gives rise to a complex series of events, including internalization of the entire IC by the acceptor cells (35) (36) (37) (38) (39) (40) (41) (42) . If the internalized IC substrates are large (e.g., IgG-opsonized cells), this process is called phagocytosis and is mediated by the zipper mechanism in which the phagocytic cell surrounds and engulfs the target cell by making continuous contact with IgG ligands distributed across the target cell. If the substrates are smaller, the reaction has been described as endocytosis or macropinocytosis, which involves less dramatic changes in the acceptor cell membrane. In all of these reactions, the entire particulate or soluble IC is internalized by the acceptor cells. However, more than 30 years ago Griffin et al. reported that crosslinked and capped polyclonal IgG complexes bound to surface Ags on lymphocytes were processed in a very different fashion: the macrophages "removed the immune complex caps from the lymphocyte without destroying the lymphocyte" (36) . Moreover, they found that this reaction was abrogated if Fc␥R on the acceptor macrophages were blocked; their findings could perhaps be considered the first report of trogocytosis, long before the term was coined. We also note that in the present study, based on recovery of donor cells, there was no indication of phagocytosis of donor cells promoted by THP-1 cells; rather, the transfer of PKH26-and Al488-labeled mAbs can best be explained by trogocytosis.
Our present results suggest that when cells are opsonized with mAbs, the reaction described by Griffin et al. can occur even if secondary agents are not used to crosslink and cap the substrate cell-bound IgG. That is, recognition of bound IgG on the opsonized cells by Fc␥R on the acceptor cells generates what appear to be immunologic synapses (Fig. 1I) . After formation of the immunologic synapse, target cell Ag, bound mAb IgG, and fragments of target cell membrane can be removed and internalized by the acceptor cell (Figs. 1, 7, and 11) . Moreover, during this process there is negligible internalization of bound mAbs by the donor cells (Fig. 8) . In the present study and in our earlier reports we have postulated a role for Fc␥RI in this process (5, 43) . Human IgG can effectively suppress transfer of both Al488 mAb and PKH26 from donor cells to acceptor cells (Figs. 3, 4, 9, and 12) . Furthermore, our results based on the use of mAb M22, which binds to Fc␥RI at a site not blocked by human IgG, demonstrate that Fc␥RI is indeed internalized by the acceptor cells following the trogocytosis reaction (Fig. 10) , thus providing support for its role in trogocytosis. In agreement with our previous study in the RTX/Z138 cell system (5), shaving is abrogated when donor cells are opsonized with F(abЈ) 2 of CET or TRA (Fig. 6 ), again indicating a role for Fc␥R on acceptor cells recognizing mAb-opsonized cells. Internalization of the F(abЈ) 2 by the donor cells is quite unlikely; we note that previous reports of antigenic modulation indicated that intact IgG mAbs were required to promote monocyte-mediated loss of targeted epitiopes (44) . Attempted blockade of Fc␥RI or Fc␥RII with specific mAbs at concentrations of 30 g/ml only modestly inhibited trogocytosis (Fig. 5) , likely due to higher avidity binding of clustered mAb on the opsonized donor cells to Fc␥R on the THP-1 cells. However, substantial blockade was evident when high concentrations of human IgG were used, and, as human IgG can contain aggregates (32), these higher concentrations may have allowed for more effective interaction with and blockade of Fc␥RI.
Based on these considerations, it would seem that shaving/ trogocytosis of mAb-opsonized cells might not occur in vivo, where the concentrations of IgG in the bloodstream can be ϳ10 mg/ml, thus potentially blocking the action of Fc␥RI. However, we emphasize that shaving of RTX-opsonized cells and antigenic modulation of T101-opsonized cells were first reported based on clinical observations (6, 7, 14) , not in vitro experiments. It is therefore likely that certain compartments within the body (perhaps the sinusoids of the liver) allow for close contact between mAb-opsonized cells and Fc␥RI-expressing acceptor cells such as Kupffer cells, thus promoting shaving. We also note that several studies in mouse models have revealed that Fc␥RI-expressing acceptor cells can play roles in processing of IgG-opsonized substrates (45) (46) (47) , despite the high concentrations of IgG in the bloodstream.
An important question emerges from this work: How do effector cells "decide" the fate of IgG-opsonized substrate cells? A voluminous literature reveals that fixed tissue macrophages such as Kupffer cells in the liver and macrophages in the spleen clear IgGopsonized cells (48 -52) , and our clinical investigations have demonstrated that infusion of just 30 mg of RTX promotes rapid clearance of circulating malignant B cells in patients with CLL (6, 7). However, our findings suggested that fixed tissue macrophages may also mediate shaving, because we found that CLL B cells not cleared in the first 15-30 min of RTX infusion lost substantial amounts of CD20, suggesting that clearance and shaving occur simultaneously (7) .
One factor that may determine whether an opsonized target is cleared or shaved may be its size. If the target is sufficiently small (e.g., an IgG-opsonized sheep erythrocyte, bacterium, or virus), then it is likely that the entire particle will be internalized by the zipper phagocytic mechanism. However, if the target is a malignant cell opsonized with many copies of a single mAb, and the target cell is comparable in size or larger than the monocyte/macrophage, then it is likely that the acceptor cell may instead ingest only small pieces of the target cell. Indeed, Wallace et al. examined the processing of IgG-opsonized breast cancer cells by human macrophages and reported that the macrophages appeared to be "chipping away" at these substrates and then internalizing the pieces (53) .
Another important factor likely affecting the relative amounts of cell clearance vs shaving is the burden of cells that are targeted by a given mAb (6, 54 -57) . If the initial burden of circulating malignant cells is high (e.g., in CLL) and is restored by reequilibration after first-pass clearance mediated by a mAb such as RTX (6, 7) , then the phagocytic capacity of the liver and spleen as well as the cytolytic capacity of NK cells are likely to be exceeded. Indeed, Bowles and Weiner have reported that CD16 (Fc␥RIII) is substantially down-regulated on NK cells after reaction with RTXopsonized cells (56) . Berdeja et al. have also reported that soon after RTX infusion, the cytolytic capacity of NK cells is reduced considerably (57) . Thus, under conditions in which effector mechanisms that clear cells are saturated or exhausted, shaving/trogocytosis may be the default reaction.
There are reports of apparent shaving of cancer cells in solid tumors. We have found, for example, based on a SCID mouse model, that infusion of RTX can lead to loss of CD20 on Z138 cells growing in a solid tumor (43) . Laurent et al. have reported that mature B lymphocytes lacking CD20 were demonstrable in nodular lymphoid infiltrates in the bone marrow of patients after treatment with RTX (58). Bertram et al. found that mAb T101 promoted antigenic modulation (loss of CD5) on malignant T cells growing in tumors of patients with cutaneous T cell lymphoma (14) . Taken together with the present report, these findings may have important implications for the use of mAbs such as RTX, TRA, and CET in cancer immunotherapy for solid tumors. An important question centers on the accessibility of mAb-opsonized cells in such tumors to effector cells such as NK cells, monocytes, and macrophages. It is possible that local saturation of effector cell cytotoxic capacity within the tumors can promote shaving, and analyses of fine-needle aspirates or biopsies of tumors after mAb treatment may address this issue.
Finally, the mechanism(s) of action of immunotherapeutic mAbs as well as the rate at which they kill tumor cells are also likely to influence whether they can mediate shaving, as well as the degree to which shaving can reduce killing efficacy. Although recent evidence supports a role for Ab-dependent cellular cytotoxicity in the cytotoxic action of both CET and TRA, these mAbs may also promote direct cell killing by binding to target sites on cells, thus setting off signaling cascades that can induce apoptosis, or block cell growth and proliferation (15) (16) (17) (18) . If these cytotoxic processes are sufficiently effective, then the targeted cells may be killed more rapidly than they can be shaved, or any shaving that does occur may not be sufficient to prevent killing. However, shaving may reduce killing efficacy, and this possibility should be considered in the design of clinical trials and their correlative studies (7) .
In summary, our experiments demonstrate that the three newly tested mAb/cell substrate pairs are all subject to trogocytosis/shaving by acceptor monocytes, as we previously reported for the RTX/B cell system. However, we did observe quantitative differences in the degree of shaving for these systems, and we cannot at this time predict whether binding of an IgG mAb to a particular epitope on a cell will in fact promote effector cell-mediated shaving/trogocytosis. The mAbs used in the present studies include one mouse IgG2a (T101) and three human IgG1 isotypes, and strong interaction with Fc␥RI would therefore appear to be one prerequisite. However, the nature of the epitope targeted by the mAb, the disposition of the epitope within the cell membrane, and the lifetime of the mAb when it binds to the cells are all likely to be important. If mAb binding promotes rapid cell killing or if mAb binding is followed by internalization, or shedding, then trogocytosis/shaving may be minimized. Many other factors can also influence these reactions and a more complete understanding of these issues may allow for the improved design of immunotherapeutic mAbs targeted to malignant cells.
